Peptide Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Type, By Region and Competition, 2020-2030F

Description

The Global Peptide Drug Conjugates Market was valued at USD 625.29 Million in 2024 and is projected to reach USD 1,347.15 Million by 2030, growing at a CAGR of 13.65% during the forecast period. This market is experiencing substantial growth due to rising demand for targeted therapies and innovation in drug delivery technologies. Peptide Drug Conjugates (PDCs) represent a novel class of therapeutics that combine the selective targeting ability of peptides with the cytotoxic potency of anti-cancer agents. By improving specificity toward diseased cells while sparing healthy tissue, PDCs offer a superior safety and efficacy profile over traditional chemotherapy. The increasing global burden of cancer, alongside the shift toward precision medicine, is fueling research and development in this space. PDCs have gained momentum as a follow-up to antibody-drug conjugates (ADCs), offering smaller, more adaptable molecules with enhanced tissue penetration and reduced immunogenicity. Their application is expanding rapidly, particularly in oncology, where treatment efficacy, reduced toxicity, and improved patient compliance are paramount.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 625.29 Million
Market Size 2030	USD 1347.15 Million
CAGR 2025-2030	13.65%
Fastest Growing Segment	Therapeutic
Largest Market	North America

Key Market Drivers

Rising Incidence of Cancer

The escalating global incidence of cancer is a major driver of the peptide drug conjugates market. As cancer remains one of the leading causes of morbidity and mortality, there is a pressing need for therapies that are both effective and less toxic. Traditional chemotherapy often lacks precision, affecting both cancerous and healthy cells, which results in severe side effects. In contrast, PDCs are engineered for targeted delivery, directing cytotoxic agents specifically to cancer cells and thereby minimizing damage to healthy tissues.

This targeted approach improves patient outcomes and quality of life. According to recent projections from the International Agency for Research on Cancer (IARC), approximately 35 million new cancer cases are expected globally by 2050-a 77% increase from 2022 figures. This upward trend is creating strong demand for safer and more effective treatment modalities, positioning PDCs as a compelling therapeutic solution.

Key Market Challenges

High Development Costs

One of the primary challenges in the peptide drug conjugates market is the high cost associated with their development. The process involves complex synthesis techniques, peptide-drug conjugation, and comprehensive preclinical and clinical evaluation. These stages are time-consuming and capital-intensive, posing significant barriers for small and mid-sized companies.

Large pharmaceutical companies currently dominate this space due to their greater financial resources and ability to manage the high risks and costs. However, innovation can be fostered through strategic collaborations, public-private partnerships, and advancements in development technologies that reduce manufacturing complexity and cost. Addressing the cost barrier will be crucial to facilitating wider adoption and broader participation in the market.

Key Market Trends

The Increasing Focus on Targeted Therapies

A major trend driving growth in the PDC market is the continued shift toward targeted therapies. PDCs exemplify this trend by offering precise drug delivery that minimizes systemic toxicity. The therapeutic peptides used in PDCs can be engineered to bind selectively to overexpressed receptors on cancer cells, ensuring localized action of the therapeutic payload.

This targeted mechanism mirrors the success of monoclonal antibodies in oncology and is further enhanced by the smaller size and better tissue penetration capabilities of peptides. PDCs are now being developed not only for oncology but also for diagnostic applications, utilizing radiolabeled or imaging agents for precise disease localization. This trend underscores the expanding versatility and potential of PDCs in personalized medicine.

Key Market Players

Novartis AG
Bicycle Therapeutics PLC
AstraZeneca PLC
Cybrexa Therapeutics Inc
Oncopeptides Inc.
Angiochem Inc.
Innovasium Soricimed Biopharma
Theratechnologies Inc.
Coherent Biopharma Co. Ltd
Wuxi STA

Report Scope:

In this report, the Global Peptide Drug Conjugates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Drug Conjugates Market, By Product:

Lutetium
Melflufen
ANG1005
BT1718
CBX-12
Other Pipeline Products

Peptide Drug Conjugates Market, By Type:

Therapeutic
Diagnostic

Peptide Drug Conjugates Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Drug Conjugates Market.

Available Customizations:

Global Peptide Drug Conjugates market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Drug Conjugates Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline Products)
- 5.2.2. By Type (Therapeutic, Diagnostic)
- 5.2.3. By Company (2024)
- 5.2.4. By Region
5.3. Market Map

6. North America Peptide Drug Conjugates Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Type
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Peptide Drug Conjugates Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product
    - 6.3.1.2.2. By Type
- 6.3.2. Mexico Peptide Drug Conjugates Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product
    - 6.3.2.2.2. By Type
- 6.3.3. Canada Peptide Drug Conjugates Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product
    - 6.3.3.2.2. By Type

7. Europe Peptide Drug Conjugates Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Type
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France Peptide Drug Conjugates Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product
    - 7.3.1.2.2. By Type
- 7.3.2. Germany Peptide Drug Conjugates Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product
    - 7.3.2.2.2. By Type
- 7.3.3. United Kingdom Peptide Drug Conjugates Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product
    - 7.3.3.2.2. By Type
- 7.3.4. Italy Peptide Drug Conjugates Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product
    - 7.3.4.2.2. By Type
- 7.3.5. Spain Peptide Drug Conjugates Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product
    - 7.3.5.2.2. By Type

8. Asia-Pacific Peptide Drug Conjugates Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Type
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Peptide Drug Conjugates Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product
    - 8.3.1.2.2. By Type
- 8.3.2. India Peptide Drug Conjugates Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product
    - 8.3.2.2.2. By Type
- 8.3.3. South Korea Peptide Drug Conjugates Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product
    - 8.3.3.2.2. By Type
- 8.3.4. Japan Peptide Drug Conjugates Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product
    - 8.3.4.2.2. By Type
- 8.3.5. Australia Peptide Drug Conjugates Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product
    - 8.3.5.2.2. By Type

9. South America Peptide Drug Conjugates Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Type
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Peptide Drug Conjugates Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product
    - 9.3.1.2.2. By Type
- 9.3.2. Argentina Peptide Drug Conjugates Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product
    - 9.3.2.2.2. By Type
- 9.3.3. Colombia Peptide Drug Conjugates Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product
    - 9.3.3.2.2. By Type

10. Middle East and Africa Peptide Drug Conjugates Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Type
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Peptide Drug Conjugates Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product
    - 10.3.1.2.2. By Type
- 10.3.2. Saudi Arabia Peptide Drug Conjugates Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product
    - 10.3.2.2.2. By Type
- 10.3.3. UAE Peptide Drug Conjugates Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product
    - 10.3.3.2.2. By Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product

15. Competitive Landscape

15.1. Novartis AG.
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
15.2. Bicycle Therapeutics PLC
15.3. AstraZeneca PLC
15.4. Cybrexa Therapeutics Inc
15.5. Oncopeptides Inc.
15.6. Angiochem Inc.
15.7. Innovasium Soricimed Biopharma
15.8. Theratechnologies Inc.
15.9. Coherent Biopharma Co. Ltd
15.10. Wuxi STA